ESPR vs PEG · rev $332.3M vs P/E 18, rev $10.29B
Esperion Therapeutics Inc (ESPR) versus Public Service Enterprise Group Inc (PEG) — a side-by-side from cached financials, not a winner call.
Esperion Therapeutics Inc (ESPR) is a drug manufacturers - specialty & generic company listed on NASDAQ.
Public Service Enterprise Group Inc (PEG) is a utilities - regulated electric company listed on NYSE.
Latest reported ESPR revenue for 2024-12-31 was $332.3M. Net income was -$51.7M. Revenue was up 185.7% from 2023-12-31 to 2024-12-31. ESPR currently screens at market cap $816.9M.
Latest reported PEG revenue for 2024-12-31 was $10.29B. Net income was $1.77B. Revenue was down 8.4% from 2023-12-31 to 2024-12-31. PEG currently screens at market cap $39.57B and trailing P/E 17.6.
ESPR currently screens at market cap $816.9M. PEG currently screens at market cap $39.57B and trailing P/E 17.6.
Not investment advice. Open the ESPR and PEG stock pages for the full models.
Not investment advice.